Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Comparison of glucose consumption and lactate production in culture medium of HL-1 cells exposed to LG, NG, HG and IHG between short- (12h) and long-time (72h) glucose treatment. by Patrick Mordel (17020879)

High glucose-containing media decreases mitochondrial membrane potential and ATP levels of in mixed glia cultures. by Yung-Cheng Huang (3443450)

Retinoic acid alleviates decreases of phospho-Akt and phospho-Bad expression caused by MCAO damage. by Ju-Bin Kang (16021324)

“…Molecular weight (kDa) are depicted at right. Data (<i>n</i> = 5) are represented as mean ± S.E.M. *<i>p</i> < 0.001, **<i>p</i> < 0.01 vs. vehicle + sham animals, #<i>p</i> < 0.01 vs. vehicle + MCAO animals.…”

Primary endpoint analysis, i.e., time to first occurrence of combined event of 50% decrease in eGFR or ESRD. by Rozita Mohd (7411322)

Effects of TGF-β1 on the expression of fibrosis indicators in HBdSMCs and the effects of MEL on the expression of fibrosis indicators in HBdSMCs induced by TGF-β1. by Yang Zhang (30734)

<i>Kpna1</i> KO mice show decreased anxiety-like behavior in the elevated plus maze. by Koki Sakurai (11690201)

DGAT-1 Inhibitor A922500 decreases the pro-inflammatory profile and cell death induced by SARS-CoV-2 infection and reduces the viral load in human monocyte. by Suelen Silva Gomes Dias (9928813)

SUR1Δ/LDLR^-/- mice have increased fasting glucose levels and impaired glucose tolerance with decreased insulin secretion. by Erika Gurzeler (4781904)

TPI demalonylation at K56 decreases PPP flux in CDCP1+ CSCs and is indispensable for postchemotherapeutic recurrence. by WenChao Gao (7321640)

HSP90 inhibition by RGRN-305 decreased the gene expression of proinflammatory cytokines induced by SARS-CoV-2 S protein. by Hakim Ben Abdallah (14578241)